Skip to main content
PMC home page
Thorax logoLink to Thorax
. 1999 Jan;54(1):20–26. doi: 10.1136/thx.54.1.20

24 hour and fractionated profiles of adrenocortical activity in asthmatic patients receiving inhaled and intranasal corticosteroids

A Wilson 1, B Lipworth 1
PMCID: PMC1745359  PMID: 10343626

Abstract

BACKGROUND—As both rhinitis and asthma are allergic conditions, they frequently occur together. The objective of this study was to assess the diurnal adrenocortical activity in asthmatics receiving inhaled (inh) and intranasal (n) formulations of two different corticosteroids, fluticasone propionate (FP) and triamcinolone acetonide (TAA), both given at clinically recommended doses.
METHODS—Twelve stable moderately severe asthmatic subjects of mean age 23.9 years and mean forced expiratory volume in one second (FEV1) 84% predicted were recruited into a randomised placebo (PL) controlled two-way crossover study comparing nPL + inhPL, nPL + inhFP (880 µg bid), and nFP (200 µg once daily) + inhFP (880 µg bid) with nPL + inhPL, nPL + inhTAA (800 µg bid) and nTAA (220 µg once daily) + inhTAA (800 µg bid), each given for five days with a 10 day washout period. Twenty four hour integrated and fractionated (overnight, 08.00 hours, daytime) serum cortisol levels and urinary cortisol/creatinine excretion were measured.
RESULTS—For 24 hour and fractionated serum cortisol levels and corrected urinary cortisol/creatinine excretion there were significant (p<0.05) differences between all active treatments and placebo. For 24 hour integrated serum cortisol levels the ratio between inhaled TAA and FP was 2.3 fold (95% CI 1.2 to 4.3), and for 24hour urinary cortisol/creatinine excretion the ratio was two-fold (95% CI 1.2 to 3.4). For 24 hour urinary cortisol excretion, with all active treatments, individual abnormal low values of <40 nmol (<14.4 µg) occurred in 17/24 with FP compared with 4/24 with TAA (p<0.0005). The 24 hour serum cortisol profile was flattened by FP but not with TAA. The addition of nasal corticosteroid did not produce further significant suppression of mean cortisol values, although with intranasal FP there were three more abnormal values for 24 hour urinary cortisol excretion than with inhaled FP alone.
CONCLUSIONS—Both inhaled FP and TAA caused significant suppression of adrenocortical activity which was twice as great with FP, the latter being associated with significantly more individual abnormal values and loss of the normal diurnal circadian rhythm. Fractionated serum cortisol levels and urinary cortisol/creatinine excretion were as sensitive as the respective integrated 24 hour measurements. Although the addition of intranasal formulations did not produce further significant suppression of mean values, there were more individual abnormal cortisol values associated with the addition of intranasal FP.



Full Text

The Full Text of this article is available as a PDF (131.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ayres J. G., Bateman E. D., Lundbäck B., Harris T. A. High dose fluticasone propionate, 1 mg daily, versus fluticasone propionate, 2 mg daily, or budesonide, 1.6 mg daily, in patients with chronic severe asthma. International Study Group. Eur Respir J. 1995 Apr;8(4):579–586. [PubMed] [Google Scholar]
  2. Barnes N. C., Marone G., Di Maria G. U., Visser S., Utama I., Payne S. L. A comparison of fluticasone propionate, 1 mg daily, with beclomethasone dipropionate, 2 mg daily, in the treatment of severe asthma. International Study Group. Eur Respir J. 1993 Jun;6(6):877–885. [PubMed] [Google Scholar]
  3. Broide J., Soferman R., Kivity S., Golander A., Dickstein G., Spirer Z., Weisman Y. Low-dose adrenocorticotropin test reveals impaired adrenal function in patients taking inhaled corticosteroids. J Clin Endocrinol Metab. 1995 Apr;80(4):1243–1246. doi: 10.1210/jcem.80.4.7714095. [DOI] [PubMed] [Google Scholar]
  4. Brown P. H., Blundell G., Greening A. P., Crompton G. K. Screening for hypothalamo-pituitary-adrenal axis suppression in asthmatics taking high dose inhaled corticosteroids. Respir Med. 1991 Nov;85(6):511–516. doi: 10.1016/s0954-6111(06)80269-6. [DOI] [PubMed] [Google Scholar]
  5. Clark D. J., Clark R. A., Lipworth B. J. Adrenal suppression with inhaled budesonide and fluticasone propionate given by large volume spacer to asthmatic children. Thorax. 1996 Sep;51(9):941–943. doi: 10.1136/thx.51.9.941. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Clark D. J., Grove A., Cargill R. I., Lipworth B. J. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax. 1996 Mar;51(3):262–266. doi: 10.1136/thx.51.3.262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Clark D. J., Lipworth B. J. Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients. Thorax. 1997 Jan;52(1):55–58. doi: 10.1136/thx.52.1.55. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Fabbri L., Burge P. S., Croonenborgh L., Warlies F., Weeke B., Ciaccia A., Parker C. Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. International Study Group. Thorax. 1993 Aug;48(8):817–823. doi: 10.1136/thx.48.8.817. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Grahnén A., Eckernäs S. A., Brundin R. M., Ling-Andersson A. An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers. Br J Clin Pharmacol. 1994 Dec;38(6):521–525. doi: 10.1111/j.1365-2125.1994.tb04393.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Grebe S. K., Feek C. M., Durham J. A., Kljakovic M., Cooke R. R. Inhaled beclomethasone dipropionate suppresses the hypothalamo-pituitary-adrenal axis in a dose dependent manner. Clin Endocrinol (Oxf) 1997 Sep;47(3):297–304. doi: 10.1046/j.1365-2265.1997.2391059.x. [DOI] [PubMed] [Google Scholar]
  11. Hanania N. A., Chapman K. R., Kesten S. Adverse effects of inhaled corticosteroids. Am J Med. 1995 Feb;98(2):196–208. doi: 10.1016/S0002-9343(99)80404-5. [DOI] [PubMed] [Google Scholar]
  12. Honour J. W. Hypothalamic-pituitary-adrenal axis. Respir Med. 1994 Aug;88 (Suppl A):9–15. doi: 10.1016/s0954-6111(05)80035-6. [DOI] [PubMed] [Google Scholar]
  13. Lipworth B. J. Airway and systemic effects of inhaled corticosteroids in asthma: dose response relationship. Pulm Pharmacol. 1996 Feb;9(1):19–27. doi: 10.1006/pulp.1996.0002. [DOI] [PubMed] [Google Scholar]
  14. Lipworth B. J. Pharmacokinetics of inhaled drugs. Br J Clin Pharmacol. 1996 Dec;42(6):697–705. doi: 10.1046/j.1365-2125.1996.00493.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Lipworth B. J., Seckl J. R. Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids. Thorax. 1997 May;52(5):476–482. doi: 10.1136/thx.52.5.476. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. McIntyre H. D., Mitchell C. A., Bowler S. D., Armstrong J. G., Wooler J. A., Cowley D. M. Measuring the systemic effects of inhaled beclomethasone: timed morning urine collections compared with 24 hour specimens. Thorax. 1995 Dec;50(12):1280–1284. doi: 10.1136/thx.50.12.1280. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Mygind N. Glucocorticosteroids and rhinitis. Allergy. 1993 Oct;48(7):476–490. doi: 10.1111/j.1398-9995.1993.tb01103.x. [DOI] [PubMed] [Google Scholar]
  18. Olsson B. Aerosol particle generation from dry powder inhalers: can they equal pressurized metered dose inhalers? J Aerosol Med. 1995 Sep;8 (Suppl 3):S13–S19. doi: 10.1089/jam.1995.8.suppl_3.s-13. [DOI] [PubMed] [Google Scholar]
  19. Wilson A. M., McFarlane L. C., Lipworth B. J. Dose-response effect for adrenal suppression with repeated twice daily inhaled fluticasone propionate and triamcinolone acetonide in adult asthmatics. Am J Respir Crit Care Med. 1997 Oct;156(4 Pt 1):1274–1277. doi: 10.1164/ajrccm.156.4.97-03029. [DOI] [PubMed] [Google Scholar]
  20. Wilson A. M., McFarlane L. C., Lipworth B. J. Effects of low and high doses of inhaled flunisolide and triamcinolone acetonide on basal and dynamic measures of adrenocortical activity in healthy volunteers. J Clin Endocrinol Metab. 1998 Mar;83(3):922–925. doi: 10.1210/jcem.83.3.4637. [DOI] [PubMed] [Google Scholar]
  21. Wilson A. M., McFarlane L. C., Lipworth B. J. Effects of repeated once daily dosing of three intranasal corticosteroids on basal and dynamic measures of hypothalamic-pituitary-adrenal-axis activity. J Allergy Clin Immunol. 1998 Apr;101(4 Pt 1):470–474. doi: 10.1016/S0091-6749(98)70354-9. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES